Abstract：
UNASSIGNED: To characterize the ocular inflammatory manifestations of inflammatory bowel disease (IBD) and examine the impact of ocular inflammation on IBD treatment.
UNASSIGNED: A single-center retrospective chart review of patients with an IBD diagnosis and ophthalmology visit between January 2016 and January 2022 was conducted. Patients with a diagnosis of uveitis, scleritis, or peripheral ulcerative keratitis (PUK) confirmed by an optometrist or ophthalmologist were included.
UNASSIGNED: Charts of 1320 IBD patients were reviewed; 42 patients with uveitis, 2 patients with scleritis, and 2 patients with PUK were identified. Anterior uveitis was the most common form of uveitis (38/42, 90.5%), often in an episodic (31/38, 81.6%) and unilateral (19/38, 50.0%) pattern. Four patients (4/42, 9.5%) had posterior segment uveitis: two with panuveitis, one with intermediate uveitis, and one with posterior uveitis. Patients on systemic therapy for IBD did not routinely undergo changes to therapy following the development of ocular inflammation (27/36, 75.0%). Therapy alterations were more frequent with the development of posterior segment uveitis, scleritis, or PUK (4/6, 66.7%) compared with anterior uveitis (5/30, 16.7%). In 10 patients, uveitis onset preceded IBD diagnosis; in these patients, tumor necrosis factor (TNF) inhibitors were often used at the time of subsequent IBD diagnosis (5/10, 50.0%).
UNASSIGNED: Unilateral anterior uveitis was the most common form of ocular inflammation among patients with IBD. Development of uveitis did not routinely require modification of immunomodulatory therapies; however, therapy changes were more common with posterior segment uveitis, scleritis, and PUK.
UNASSIGNED: A single-center retrospective chart review of patients with an IBD diagnosis and ophthalmology visit between January 2016 and January 2022 was conducted. Patients with a diagnosis of uveitis, scleritis, or peripheral ulcerative keratitis (PUK) confirmed by an optometrist or ophthalmologist were included.
UNASSIGNED: Charts of 1320 IBD patients were reviewed; 42 patients with uveitis, 2 patients with scleritis, and 2 patients with PUK were identified. Anterior uveitis was the most common form of uveitis (38/42, 90.5%), often in an episodic (31/38, 81.6%) and unilateral (19/38, 50.0%) pattern. Four patients (4/42, 9.5%) had posterior segment uveitis: two with panuveitis, one with intermediate uveitis, and one with posterior uveitis. Patients on systemic therapy for IBD did not routinely undergo changes to therapy following the development of ocular inflammation (27/36, 75.0%). Therapy alterations were more frequent with the development of posterior segment uveitis, scleritis, or PUK (4/6, 66.7%) compared with anterior uveitis (5/30, 16.7%). In 10 patients, uveitis onset preceded IBD diagnosis; in these patients, tumor necrosis factor (TNF) inhibitors were often used at the time of subsequent IBD diagnosis (5/10, 50.0%).
UNASSIGNED: Unilateral anterior uveitis was the most common form of ocular inflammation among patients with IBD. Development of uveitis did not routinely require modification of immunomodulatory therapies; however, therapy changes were more common with posterior segment uveitis, scleritis, and PUK.
摘要：
■表征炎症性肠病(IBD)的眼部炎症表现,并检查眼部炎症对IBD治疗的影响。
■对2016年1月至2022年1月诊断为IBD和眼科就诊的患者进行了单中心回顾性图表回顾。诊断为葡萄膜炎的患者，巩膜炎,包括由验光师或眼科医生确认的外周溃疡性角膜炎（PUK）。
■检查了1320例IBD患者的图表；42例葡萄膜炎患者，2例巩膜炎患者，并确定了2例PUK患者。前葡萄膜炎是葡萄膜炎的最常见形式（38/42，90.5%），通常为偶发(31/38，81.6%)和单边(19/38，50.0%)模式。4例患者（4/42，9.5%）有后节葡萄膜炎：2例有全葡萄膜炎，一个患有中度葡萄膜炎，还有一个患有后葡萄膜炎.全身治疗IBD的患者在眼部炎症发展后未常规进行治疗改变(27/36,75.0%)。随着后段葡萄膜炎的发展，治疗改变更为频繁，巩膜炎,或PUK（4/6，66.7％）与前葡萄膜炎（5/30，16.7％）相比。在10名患者中，葡萄膜炎发病先于IBD诊断；在这些患者中，肿瘤坏死因子（TNF）抑制剂通常在随后的IBD诊断时使用（5/10，50.0％）。
■单侧前葡萄膜炎是IBD患者中最常见的眼部炎症形式。葡萄膜炎的发展不需要常规的免疫调节疗法的修改;然而，治疗改变更常见于后段葡萄膜炎，巩膜炎,和PUK。
■对2016年1月至2022年1月诊断为IBD和眼科就诊的患者进行了单中心回顾性图表回顾。诊断为葡萄膜炎的患者，巩膜炎,包括由验光师或眼科医生确认的外周溃疡性角膜炎（PUK）。
■检查了1320例IBD患者的图表；42例葡萄膜炎患者，2例巩膜炎患者，并确定了2例PUK患者。前葡萄膜炎是葡萄膜炎的最常见形式（38/42，90.5%），通常为偶发(31/38，81.6%)和单边(19/38，50.0%)模式。4例患者（4/42，9.5%）有后节葡萄膜炎：2例有全葡萄膜炎，一个患有中度葡萄膜炎，还有一个患有后葡萄膜炎.全身治疗IBD的患者在眼部炎症发展后未常规进行治疗改变(27/36,75.0%)。随着后段葡萄膜炎的发展，治疗改变更为频繁，巩膜炎,或PUK（4/6，66.7％）与前葡萄膜炎（5/30，16.7％）相比。在10名患者中，葡萄膜炎发病先于IBD诊断；在这些患者中，肿瘤坏死因子（TNF）抑制剂通常在随后的IBD诊断时使用（5/10，50.0％）。
■单侧前葡萄膜炎是IBD患者中最常见的眼部炎症形式。葡萄膜炎的发展不需要常规的免疫调节疗法的修改;然而，治疗改变更常见于后段葡萄膜炎，巩膜炎,和PUK。
